The course of treatment of various disorders of the peripheral or central nervous system often includes Neuromidine tablets. This drug refers to cholinesterase inhibitors. This means that the active component of the drug improves the conduct and transmission of nerve impulses, and also has a stimulating effect on smooth muscles.
Composition of Neuromidine
The active ingredient of the preparation in question is monohydrate of ipidacrine hydrochloride.
Auxiliary components:
- potato starch (14 mg);
- lactose monohydrate (65 mg);
- calcium stearate (1 mg).
For the described form of release of Neuromidine, the content of ipidacrine in one tablet is 20 mg. This concentration is sufficient to achieve the desired therapeutic effect.
The use of Neuromedin tablets
Presented medicine is prescribed for such diseases and conditions:
- mono- and polyneuropathies;
- myasthenia gravis;
- polyradiculopathy;
- bulbar paresis and paralysis;
- pathologies of the central nervous system, accompanied by cognitive or motor disorders;
- intestinal atony ;
- weak labor activity;
- memory impairment;
- dementia;
- multiple sclerosis.
Duration of treatment and dosage are set individually for each case.
The standard scheme of therapy involves taking 0.5-1 tablets from 1 to 3 times in 24 hours. Treatment is carried out for 1-6 months. At intestinal atony, the duration of the course is 2 weeks. If it is required to strengthen the contractile capacity of the uterus for the intensification of labor, the drug is used once.
Contraindications to the use of Neuromidine tablets
List of diseases in which treatment with the described drug is prohibited:
- angina pectoris;
- epilepsy ;
- Hyperkinesis on the background of extrapyramidal diseases;
- bronchial asthma;
- severe disorders of the vestibular apparatus;
- exacerbation of chronic peptic ulcer of the duodenum or stomach;
- severe bradycardia;
- propensity to allergic reactions to the components of Neuromidine;
- mechanical obstruction of the urinary tract, intestines.
Also, the drug is contraindicated in pregnant women, women during breastfeeding, adolescents and children under the age of 18.
Caution when using Neurromidine should be shown if the following pathologies exist:
- lactose intolerance;
- thyrotoxicosis;
- obstructive diseases of the respiratory organs in the anamnesis;
- cardiovascular diseases;
- lactase insufficiency;
- acute respiratory diseases;
- malobsorption syndrome isomaltose or lactose.